Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Atherosclerosis ; 216(2): 414-9, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21367421

ABSTRACT

The association between serum levels of endogenous estrogens in postmenopausal women and the subsequent risk of coronary heart disease (CHD) was examined in a prospective case-control study nested within the New York University Women's Health Study (NYUWHS). The NYUWHS is a prospective cohort study of 14,274 healthy women enrolled between 1985 and 1991. A total of 99 women who were postmenopausal and free of cardiovascular disease at enrollment and who subsequently experienced CHD, defined as non-fatal myocardial infarction (MI), fatal CHD, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG), were matched 1:2 by baseline age, blood sampling date, and postmenopausal status to controls who remained free of CHD as of the date of diagnosis of the matching case. Biochemical analyses for total estradiol, estrone, percent free estradiol, percent estradiol bound to sex hormone-binding globulin (SHBG), and SHBG were performed on pre-diagnostic stored serum samples. Participants had not used any hormone medications in the 6 months prior to blood collection. In the model adjusting only for matching factors, the risk of CHD in the top tertile of calculated bioavailable estradiol was elevated compared with the bottom tertile (OR=2.10; 95% CI=1.13-3.90, P for trend=0.03), and the risk in the top tertile of SHBG was reduced (OR=0.50, 95% CI=0.28-0.92, P for trend<0.01). However, these associations disappeared after adjusting for baseline hypertension status, body mass index, and serum cholesterol levels. These findings suggest that circulating estradiol and SHBG are not associated with CHD risk in postmenopausal women beyond what can be explained by the variation in hypertension status, BMI, and cholesterol.


Subject(s)
Coronary Disease/blood , Hormones/metabolism , Aged , Body Mass Index , Case-Control Studies , Cholesterol/metabolism , Cohort Studies , Estradiol/blood , Female , Humans , Hypertension/metabolism , Middle Aged , Myocardial Infarction/pathology , Odds Ratio , Postmenopause
2.
Fertil Steril ; 95(3): 1178-81, 2011 Mar 01.
Article in English | MEDLINE | ID: mdl-21047632

ABSTRACT

In this case-control study of euthyroid first-cycle IVF patients ≥ 38 years old with singleton baby, miscarriage, biochemical pregnancy, and no pregnancy outcomes from 2005-2008, we assayed frozen serum for autoimmune thyroid disease (AITD) and thyroid function at cycle start, trigger, and 4 and 5 weeks' gestation. AITD prevalence in older infertile women was similar across clinical outcomes, and although AITD was associated with a higher baseline TSH, TSH remained within acceptable ranges, suggesting that T(4) supplementation may not affect maternal outcomes in older euthyroid AITD patients through 5 weeks gestation.


Subject(s)
Fertilization in Vitro/statistics & numerical data , Infertility, Female/epidemiology , Pregnancy Outcome/epidemiology , Thyroid Gland/physiology , Thyroiditis, Autoimmune/epidemiology , Abortion, Spontaneous/epidemiology , Adult , Case-Control Studies , Female , Humans , Hypothyroidism/epidemiology , Infertility, Female/therapy , Maternal Age , Pregnancy , Prevalence
3.
Cancer Epidemiol Biomarkers Prev ; 18(1): 275-81, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19124509

ABSTRACT

Observational epidemiologic studies and randomized trials have reported a protective effect of oral hormonal replacement therapy on risk of colorectal cancer. Only one previous prospective study, the Women's Health Initiative Observational Study, has reported on the relationship between endogenous hormones and incident colorectal cancer. Contrary to expectation, the investigators found that women with higher circulating estradiol levels were at increased risk of developing colorectal cancer. We conducted a case-control study nested within the New York University Women's Health Study prospective cohort to evaluate the association between endogenous levels of estrone, estradiol, and sex hormone-binding globulin (SHBG) with risk of colorectal cancer. We measured hormones and SHBG in serum samples collected at enrollment from a total of 148 women who subsequently developed colorectal cancer and 293 matched controls. Circulating estrone levels were positively associated with risk of colorectal cancer: The odds ratio for the highest versus lowest quartile of estrone was 1.8 (95% confidence interval, 1.0-3.3). We found a nonsignificant inverse association between SHBG and colorectal cancer, which disappeared after adjusting for body mass index. We did not find an association between estradiol and colorectal cancer risk, but we cannot rule out a potential association because of substantial laboratory error in the measurement. Our results suggest that endogenous estrone is associated with increased risk of colorectal cancer in postmenopausal women.


Subject(s)
Biomarkers/blood , Colorectal Neoplasms/blood , Gonadal Steroid Hormones/blood , Postmenopause/blood , Case-Control Studies , Colorectal Neoplasms/epidemiology , Estradiol/blood , Estrogen Replacement Therapy , Estrone/blood , Female , Humans , Logistic Models , Middle Aged , Risk Factors , Sex Hormone-Binding Globulin/metabolism , Surveys and Questionnaires
4.
Cancer Epidemiol Biomarkers Prev ; 15(11): 2123-30, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17119037

ABSTRACT

Epidemiologic evidence suggests that a full-term pregnancy may affect maternal risk of breast cancer later in life. The objective of this cross-sectional study was to compare circulating levels of maternal hormones affecting breast differentiation (human chorionic gonadotropin and prolactin) and proliferation [alpha-fetoprotein, insulin-like growth factor I (IGF-I), and estradiol] between women at a low to moderate risk (Asians and Hispanics), as compared with women at a high risk for breast cancer (Caucasians and African-Americans). Between May 2002 and December 2004, a total of 586 pregnant women were approached during a routine prenatal visit. Among them, 450 women (206 Caucasian, 126 Asian, 88 Hispanic, and 30 African-American) met the inclusion criteria and signed the informed consent. Only singleton pregnancies were considered. Blood samples were drawn during the second trimester of pregnancy. Laboratory analyses were done using the IMMULITE 2000 immunoassay system. Gestational age standardized mean levels of estradiol, IGF-I, and prolactin were significantly higher in Hispanic women compared with Caucasian women. Mean concentration of IGF-I was significantly higher in African-American women compared with Caucasian and Asian women. No significant differences in pregnancy hormone levels were observed between Caucasian and Asian (predominantly second-generation Chinese) women in this study. Irrespective of ethnicity, women who had their first pregnancy had substantially higher mean levels of alpha-fetoprotein, human chorionic gonadotropin, estradiol, and prolactin compared with women who previously had at least one full-term pregnancy. These data suggest that circulating pregnancy hormone levels may explain some of the ethnic differences in breast cancer risk.


Subject(s)
Breast Neoplasms/blood , Breast Neoplasms/diagnosis , Breast Neoplasms/ethnology , Hormones/blood , Adult , Chorionic Gonadotropin/blood , Estradiol/blood , Ethnicity , Female , Gestational Age , Humans , Immunoassay , Incidence , Parity , Pregnancy , Prolactin/blood , alpha-Fetoproteins/biosynthesis
5.
Obstet Gynecol ; 105(2): 285-9, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15684153

ABSTRACT

OBJECTIVE: To assess the accuracy of vaginal fetal fibronectin sampling without use of a sterile speculum examination as a screening test for predicting spontaneous preterm birth. METHODS: A historical cohort of patients who were followed up with serial fetal fibronectin testing between 1998 and 2001 was identified. All patients were considered to be at high risk for preterm delivery and were screened with fetal fibronectin testing without using a speculum at 2- to 3-week intervals from 22 weeks to 32 weeks of gestation. Charts were reviewed for fetal fibronectin results and pregnancy outcome data. Groups were compared using chi(2) analysis or Fisher exact test with significance defined as P < .05. RESULTS: A total of 1,396 fetal fibronectin tests from 416 pregnancies were performed via the "blind" sampling technique. Overall, 24.9% of pregnancies delivered spontaneously before 37 weeks; 9.1% delivered spontaneously before 34 weeks. For delivery before 34 weeks of gestation, the test had a sensitivity of 44.7%, a specificity of 88.4%, a positive predictive value of 27.9%, and a negative predictive value of 94.1%. For delivery within 14 and 21 days of a single fetal fibronectin assessment, the test had a sensitivity of 52% and 45.5%, a specificity of 94.5% and 94.9%, a positive predictive value of 14.6% and 22.5%, and a negative predictive value of 99.1% and 98.2%, respectively. CONCLUSION: "Blind" vaginal fetal fibronectin sampling has high negative predictive values and specificities in predicting spontaneous preterm birth. LEVEL OF EVIDENCE: II-2.


Subject(s)
Fibronectins/analysis , Glycoproteins/analysis , Obstetric Labor, Premature/diagnosis , Pregnancy Outcome , Adult , Biomarkers/analysis , Cohort Studies , Enzyme-Linked Immunosorbent Assay , Female , Fibronectins/metabolism , Follow-Up Studies , Gestational Age , Glycoproteins/metabolism , Humans , Obstetric Labor, Premature/epidemiology , Parity , Predictive Value of Tests , Pregnancy , Prenatal Care/methods , Probability , Retrospective Studies , Risk Assessment , Sensitivity and Specificity , Vaginal Smears
6.
Int J Cancer ; 108(3): 425-32, 2004 Jan 20.
Article in English | MEDLINE | ID: mdl-14648710

ABSTRACT

Experimental and epidemiological data support a role for sex steroid hormones in the pathogenesis of endometrial cancer. The associations of pre-diagnostic blood concentrations of estradiol, estrone, testosterone, androstenedione, DHEAS and SHBG with endometrial cancer risk were investigated. A case-control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). Cases were 124 postmenopausal women with invasive endometrial cancer. For each case, 2 controls were selected, matching the case on cohort, age and date of recruitment. Only postmenopausal women who did not use exogenous hormones at the time of blood donation were included. Odds ratios (OR) and their 95% confidence intervals (CI) were estimated by conditional logistic regression. ORs (95% CI) for endometrial cancer for quartiles with the highest hormone levels, relative to the lowest were as follows: 4.13 (1.76-9.72), p(trend) = 0.0008 for estradiol, 3.67 (1.71-7.88), p(trend) = 0.0007 for estrone, 2.15 (1.05-4.40), p(trend) = 0.04 for androstenedione, 1.74 (0.88-3.46), p(trend) = 0.06 for testosterone, 2.90 (1.42-5.90), p(trend) = 0.002 for DHEAS and 0.46 (0.20-1.05), p(trend) = 0.01 for SHBG after adjustment for body mass index, use of oral contraceptives and hormone replacement therapy. The results of our multicenter prospective study showed a strong direct association of circulating estrogens, androgens and an inverse association of SHBG levels with endometrial cancer in postmenopausal women. The effect of elevated androstenedione and testosterone levels on disease risk seems to be mediated mainly through their conversion to estrogens, although an independent effect of androgens on tumor growth cannot be ruled out, in particular in the years close to diagnosis.


Subject(s)
Endometrial Neoplasms/blood , Endometrial Neoplasms/epidemiology , Gonadal Steroid Hormones/blood , Adult , Aged , Case-Control Studies , Cohort Studies , Disease Susceptibility , Female , Hormone Replacement Therapy , Humans , Italy/epidemiology , Middle Aged , Neoplasm Invasiveness , New York/epidemiology , Postmenopause , Prospective Studies , Risk Factors , Sweden/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...